MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.
Our laboratory recently reported that treatment with the d-amino acid containing peptide HYD1 induces necrotic cell death in multiple myeloma cell lines. Because of the intriguing biological activity and promising in vivo activity of HYD1, we pursued strategies for increasing the therapeutic efficacy of the linear peptide. These efforts led to a cyclized peptidomimetic, MTI-101, with increased in vitro activity and robust in vivo activity as a single agent using two myeloma models that consider the bone marrow microenvironment. MTI-101 treatment similar to HYD1 induced reactive oxygen species, depleted ATP levels, and failed to activate caspase-3. Moreover, MTI-101 is cross-resistant in H929 cells selected for acquired resistance to HYD1. Here, we pursued an unbiased chemical biology approach using biotinylated peptide affinity purification and liquid chromatography/tandem mass spectrometry analysis to identify binding partners of MTI-101. Using this approach, CD44 was identified as a predominant binding partner. Reducing the expression of CD44 was sufficient to induce cell death in multiple myeloma cell lines, indicating that multiple myeloma cells require CD44 expression for survival. Ectopic expression of CD44s correlated with increased binding of the FAM-conjugated peptide. However, ectopic expression of CD44s was not sufficient to increase the sensitivity to MTI-101-induced cell death. Mechanistically, we show that MTI-101-induced cell death occurs via a Rip1-, Rip3-, or Drp1-dependent and -independent pathway. Finally, we show that MTI-101 has robust activity as a single agent in the SCID-Hu bone implant and 5TGM1 in vivo model of multiple myeloma.
Corresponding Author: Lori A. Hazlehurst, Molecular Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL. Lori.Hazlehurst@moffitt.org.
Anthony W
AW
Gebhard
Priyesh
P
Jain
Rajesh R
RR
Nair
Michael F
MF
Emmons
Raul F
RF
Argilagos
John M
JM
Koomen
Mark L
ML
McLaughlin
Lori A
LA
Hazlehurst
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D003500:Cyclization; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009101:Multiple Myeloma / Q000378:metabolism* / Q000473:pathology*; D009336:Necrosis / Q000139:chemically induced; D009374:Neoplasms, Experimental; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D053719:Tandem Mass Spectrometry
D000970:Antineoplastic Agents; D018960:Hyaluronan Receptors; C000589259:MTI-101; D009842:Oligopeptides; D010456:Peptides, Cyclic; D017382:Reactive Oxygen Species; C546443:lysyl-isoleucyl-lysyl-methionyl-valyl-isoleucyl-seryl-tryptophyl-lysyl-glycine; D053148:Caspase 3